Global Bipolar Disorder Therapeutic Market - Projections, Drivers, Trends, Vendors, and Analysis Through 2021 by Technavio

Technavio has published a new report on the global bipolar disorder therapeutic market from 2017-2021. (Graphic: Business Wire)

???pagination.previous??? ???pagination.next???

LONDON--()--According to the latest market study released by Technavio, the global bipolar disorder therapeutic market is projected to grow to USD 6,166.89 million by 2021, at a CAGR of more than 2% over the forecast period.

This research report titled ‘Global Bipolar Disorder Therapeutic Market 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.

 
Bipolar disorder, also called manic-depressive disorder, is a mental disorder that causes unusual mood swings in patients. The global bipolar disorder therapeutic market is expected to benefit from the rising awareness of the disease, which is increasing the diagnosis rate.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Based on drug class, the report categorizes the global bipolar disorder therapeutic market into the following segments:

  • Antipsychotics
  • Anticonvulsants
  • Traditional mood stabilizers
  • Others

The top three revenue-generating drug class segments in the global bipolar disorder therapeutic market are discussed below:

Antipsychotics

Antipsychotics occupied a majority 45% of the global bipolar disorder therapeutic market in 2016 and is expected to retain its shares over the forecast period. These drugs are mainly used to manage psychotic symptoms such as delusions, hallucinations, or mania,” says Sapna Jha, a lead analyst at Technavio for central nervous system research.

Antipsychotics are often used in combination with mood stabilizers for the control and treatment of bipolar disorder. Factors such as the high dependency of these drugs in the treatment of bipolar disorder, large investments towards the R&D of this drug class, and the entry of new drugs are expected to drive the growth of the market.

Anticonvulsants

Anticonvulsants, which were originally used in the treatment of epilepsy are finding rising applications in the treatment of bipolar disorder. This class of drugs reduces the sensitivity of nerves to external stimuli, which helps greatly in controlling mania. The extensive use of anticonvulsants, as a single drug or as a part of combination therapies, will quickly drive the growth of the market segment over the forecast period. The common anticonvulsants used for manic episodes include valproic acid/Divalproex or carbamazepine.

Traditional mood stabilizers

Mood stabilizers are used to treat mood swings associated with bipolar disorder and other mental disorders. The extensive use of lithium as a first-line treatment for bipolar disorder is expected to maintain the growth rate of the market over the forecast period,” says Sapna.

Often termed as a traditional mood stabilizer, lithium is the oldest and least expensive drug used for bipolar disorder treatment. It is considered to be effective in the treatment of mania, is a proven anti-suicidal drug that reduces the tendency of suicides, and reduces the frequency and symptoms of manic episodes by 70%-80%.

The top vendors highlighted by Technavio’s research analysts in this report are:

  • Eli Lilly
  • Bristol-Myers Squibb
  • AstraZeneca

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like in-vitro diagnostics, infectious and rare diseases, and life science research tools. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

According to the latest market study released by Technavio, the global bipolar disorder therapeutic market is projected to grow to USD 6,166.89 million by 2021, at a CAGR of more than 2%.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com